
1 **Short-term versus 6-week prednisone in the treatment of subacute thyroiditis: a**
2 **randomized controlled trial**

3

4 Lian Duan^{1,2*}, Xiaoli Feng², Rui Zhang², Xiaojuan Tan², Xiaoyan Xiang², Rufe Shen²,
5 Hongting Zheng²

6 ¹Department of Endocrinology, The Third Affiliated Hospital of Chongqing Medical
7 University (Jie er Hospital), Chongqing, China

8 ²Department of Endocrinology, The Second Affiliated Hospital of Third Military Medical
9 University, Chongqing, China

10 * Corresponding authors

11

12 **Author details:**

13 Lian Duan, Shuanghu branch No.1, Yubei District, Chongqing 401120, China

14 jasonduan@hospital.cqmu.edu.cn

15 Xiaoli Feng, Xinqiao Street No.183, Shapingba District, Chongqing 400037, China

16 fengxiaoli1234@sina.com

17 Rui Zhang, Xinqiao Street No.183, Shapingba District, Chongqing 400037, China

18 81766250@qq.com

19 Xiaojuan Tan, Xinqiao Street No.183, Shapingba District, Chongqing 400037, China

20 409375013@qq.com

21 Xiaoyan Xiang, Xinqiao Street No.183, Shapingba District, Chongqing 400037, China

22 xxy_single@163.com

23 Rufe Shen, Xinqiao Street No.183, Shapingba District, Chongqing 400037, China

24 shenrufe@126.com

25 Hongting Zheng, Xinqiao Street No.183, Shapingba District, Chongqing 400037, China

26 fnf7703@hotmail.com

27

28 **Correspondence:**

29 Dr. Lian Duan, ORCID numbers: 0000-0003-4272-3461, The Third Affiliated Hospital of

30 Chongqing Medical University (Jie er Hospital), Chongqing 401120, China, e-mail:

31 jasonduan@hospital.cqmu.edu.cn, Tel: +86 02360353431, Fax: +86 02360353018

32 **Word count:** 3484

33 **Total number of figures and Tables:** 4 Figures, 1 Table and 1 Supplementary table

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49 **Abstract**

50 **Background:** Moderate-to-severe subacute thyroiditis is commonly treated with 6-8 weeks
51 glucocorticoids; however, no studies have described short-term prednisone treatment for
52 subacute thyroiditis. We evaluated the efficacy of this treatment for subacute thyroiditis.

53 **Methods:** This was a 24-week, prospective, single-blind, randomized controlled study.
54 Patients aged 18-70 years with subacute thyroiditis were hospitalized from August 2013 to
55 December 2014. Patients with moderate-to-severe symptoms were randomized to receive
56 either 30 mg/d prednisone for 1 week and then switched to 1 week of nonsteroidal
57 anti-inflammatory drugs or 6 weeks of prednisone. The primary endpoints were the
58 differences in efficacy at the end of treatment between two groups. Secondary endpoints
59 included differences between the two groups in parameters of side effects at withdrawal and
60 thyroid function at weeks 6, 12, 24.

61 **Results:** Of 96 patients screened, 52 subjects were randomized and 50 completed the study.
62 Efficacy and recurrence rates were not significantly different at withdrawal in both groups
63 ($P=0.65$). Parathyroid hormone (28.8 vs 38.9 pg/ml, $p=0.011$) and mean systolic blood
64 pressure (113.9 vs 122.4 mmHg, $p=0.023$) were significantly lower in the experimental group
65 than in the control group at discontinuation. No significant differences were observed in other
66 secondary endpoints at withdrawal and in thyroid function at the 6th, 12th and 24th week
67 during the follow-up time between the two groups.

68 **Conclusions:** Fewer side effects of glucocorticoids and similar efficacy and recurrence rates
69 were observed with short-term prednisone compared with those with 6-week treatment for

70 subacute thyroiditis. Short-term prednisone with a better safety profile may be as one
71 alternative strategy for ameliorating moderate-to-severe symptoms of subacute thyroiditis.

72 **Trial registration:** Trial registration number NCT01837433. Registered with
73 Clinicaltrials.gov on 23 April 2013

74 **Key words:** Glucocorticoid, randomized controlled study, short-term treatment, subacute
75 thyroiditis

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92 **Background**

93 Subacute thyroiditis (SAT) is the most common painful thyroid disease and is a common
94 cause of thyrotoxicosis. It is diagnosed based on the following: viral infection induction,
95 fever, thyrotoxicosis, enlarged firm thyroid, palpation pain, radiation of pain to the parietal
96 and occipital regions and to the ears, jaw, or throat, high erythrocyte sedimentation rate
97 (ESR) and elevated C-reactive protein (CRP) levels. SAT can be accompanied by mild
98 anemia, low thyroid iodine uptake rate, diffuse heterogeneous changes in ultrasonography,
99 and decreased or normal color doppler blood flow signal [1]. The American Thyroid
100 Association guidelines recommend glucocorticoid therapy (prednisone 40 mg daily for 1-2
101 weeks followed by a gradual taper over 2-4 weeks or longer, depending on clinical response)
102 for patients in whom nonsteroidal anti-inflammatory drugs (NSAIDs) show poor efficacy or
103 for those with moderate-to-severe symptoms at onset [2]. The Chinese guidelines recommend
104 starting therapy with 20-40 mg/d prednisone for 1-2 weeks and then slowly reducing
105 according to symptoms, signs and ESR. The usual course is 6-8 weeks. However, at least
106 20% of patients have a course of treatment longer than 8 weeks in one study [3].
107 at least 20% of patients have a course of treatment greater than eight weeks

108 However, long-term glucocorticoids can increase blood glucose, blood pressure, blood
109 lipid levels, bone metabolism disorders [4], and cause Cushing's features, chronic
110 hypoadrenocorticism, and even acute adrenal crisis [5]. Therefore an ideal therapy would
111 limit the duration of treatment. Thus far, no randomized controlled trials (RCTs) investigating
112 short-term glucocorticoid treatment protocols are available. We therefore conducted a RCT to
113 assess the efficacy and safety of short-term prednisone therapy for moderate-to-severe SAT.

114 **Methods**

115 **Study design and participants**

116 We conducted a 24-week prospective, single-blind, randomized controlled clinical trial at the
117 department of endocrinology, the second affiliated hospital, third military medical university,
118 Chongqing, China. This study was approved by the ethics committee of the second affiliated
119 hospital, third military medical university (reference number 2018012-01). All patients
120 signed written informed consent forms according to the tenets of the Declaration of Helsinki.
121 SAT was diagnosed based on diagnostic criteria [2]. The severity of SAT was scored [6] as
122 follows: fever – none 0 point, $<38^{\circ}\text{C}$ 1 point, and $>38^{\circ}\text{C}$ 2 points; tenderness – none 0 point,
123 mild 1 point, and severe 2 points; goiter by ultrasonography or palpation – none 0 point and
124 yes 1 point; and ESR – normal 0 point, 25-60 mm/h 1 point, and >60 mm/h 2 points. 18-70
125 years patients with SAT scored ≥ 3 points were included. Patients who were diagnosed with
126 diabetes, an active peptic ulcer, a tumor, hepatic dysfunction, recurrent SAT and those who
127 were already taking glucocorticoids were excluded.

128 Moderate-to-severe SAT was defined by us as a definite diagnosis of SAT, with a sore
129 thyroid, and a score ≥ 3 points. Efficacy was defined as no pain in the thyroid region,
130 disappearance of clinical symptoms such as thyroid tenderness [7], and normalization of ESR
131 and/or CRP level. Recurrence was defined as the development of a goiter with tenderness at
132 the neck, fever, and re-elevation of inflammatory markers during prednisone tapering or after
133 therapy withdrawal [8]. Anemia was defined as a hemoglobin (Hb) level <130 g/L for males
134 and <120 g/L for females [9]. Overt and subclinical hyperthyroidism were defined as
135 decreased serum thyroid-stimulating hormone (TSH) levels with elevated or normal levels of

136 free triiodothyronine (FT3) and/or free thyroxine (FT4) (1). Subclinical hypothyroidism was
137 characterized by a TSH level above the upper reference limit in combination with a normal
138 FT4 level. An elevated TSH level (>10 mIU/L) in combination with a subnormal FT4 level
139 characterized overt hypothyroidism [10]. Persistent hypothyroidism was defined by us as
140 hypothyroidism that continued after the 24-week follow-up.

141 **Randomization and masking**

142 Patients were randomly assigned to short-term or 6-week prednisone treatment (Fig. 1) in
143 accordance with a random number and masked to randomization and treatment allocation.

144 **Procedures**

145 The patients with moderate-to-severe SAT were treated as follows: 1) those in the
146 experimental group received 20 mg prednisone in the morning and 10 mg in the afternoon,
147 daily for 1 week. In the 2nd week they received 400 mg celecoxib on the 1st day and 200 mg
148 twice daily during the remaining 6 days until celecoxib withdrawal; and 2) those in the
149 control group received 20 mg prednisone in the morning and 10 mg in the afternoon, daily in
150 the 1st week. The dose was then reduced by 5 mg/week from the 2nd week until withdrawal
151 in the 6th week. All patients were followed up for 24 weeks after initial treatment (Fig. 2).
152 The experimental group had five followed-up visits. ESR, CRP and cortisol (8 am) were
153 surveyed in the 1st and 2nd week after the initial treatment. Glycated albumin (GA), blood
154 glucose, bone metabolism, blood lipids, and blood pressure were investigated in the 2nd week
155 after the initial treatment. The control group had four follow-up visits. ESR, CRP and cortisol
156 (8 am) were surveyed in the 1st week after the initial treatment. GA, blood glucose, bone
157 metabolism, blood lipids, blood pressure and cortisol (8 am) were investigated in the 6th

158 week after the initial treatment. Thyroid function was measured in the 6th, 12th and 24th
159 week after the initial treatment in both groups. Each group lost one patient during the
160 follow-up because of poor compliance, resulting in a total of 50 patients completing the
161 follow-up. Proton pump inhibitors were administered to all patients. Relapsed patients were
162 administered prednisone 10 mg twice daily and tapered by 5 mg/week after symptom control
163 for 4 weeks during treatment and after withdrawal.

164 **Outcomes**

165 The primary endpoints were the differences between the two groups in efficacy and
166 recurrence rates at the end of treatment. The secondary endpoints included differences
167 between the two groups in cortisol, total cholesterol (TC), triglyceride (TG) levels, systolic
168 blood pressure (SBP), diastolic blood pressure (DBP), β cross-linked C-telopeptide of type
169 1 collagen (BCTX), osteocalcin (OC), type I procollagen amino terminal peptide (PINP),
170 parathyroid hormone (PTH), 25-hydroxy vitamin D (25-OH-VD), calcitonin (CT), peripheral
171 blood glucose, GA levels, and thyroid function [FT3, FT4, TSH, serum anti-thyroglobulin
172 antibody (TGAb), serum anti-thyroid peroxidase antibody (TPOAb), thyroid-binding globulin
173 (TBG), and serum anti-TSH receptor antibody (TRAb) levels].

174 **Statistical analysis**

175 Based on past intervention trials [11-17], the sample numbers ranged from 5 to 49 cases. The
176 approximate number of hospitalized patients with SAT in our department was 50 per year.
177 Considering that 5% of patients may have been lost during follow-up, we decided to include
178 52 patients.

179 Data with a normal distribution were presented with means and standard deviations

180 ($\bar{x} \pm s$), and data with a skewed distribution were presented with medians and interquartile
181 ranges (P25-P75). Categorical data were presented by numbers and percent (%). Two
182 independent sample t-tests and two independent sample Wilcoxon rank sum tests were
183 performed to compare the difference between the two treatment groups for the continuous
184 data with normal distributions and those with skewed distributions, respectively. Fisher's
185 exact test was performed to assess the associations of categorical data with treatment groups.
186 The changes between two time points within the treatment groups were evaluated by a paired
187 t-test, and the non-parametric Wilcoxon signed ranks test, respectively, for continuous data
188 with normal distributions, and for the data with a skewed distributions. A generalized linear
189 mixed model was used to test repeated measures of data due to missing values. Statistical
190 analyses were evaluated at a two-sided significance level of 0.05 and were performed using
191 SAS 9.4 software (SAS Institute Inc., Cary, NC, USA).

192 **Results**

193 **Baselines**

194 From August 1, 2013, to December 31, 2014, 96 hospitalized individuals were screened for
195 eligibility. In total, 30 cases with mild symptoms whose scores were less than 3 points were
196 ineligible. Furthermore, 14 cases were excluded because of recent use of glucocorticoids,
197 diabetes mellitus, hepatic dysfunction, recurrent SAT with unilateral thyroidectomy, active
198 peptic ulcer, and a tumor. Thus, 52 patients with moderate-to-severe SAT were randomized to
199 the experimental and control groups in the study. Finally, data were obtained from 50 patients
200 (Fig. 1). The two groups had comparable ages, male to female proportions, severity scores,
201 radioiodine uptake (RAIU) at 3 and 24 h, Hb, TPOAb, TGAAb, TBG, and TRAb levels (Table

202 1).

203 **Primary endpoints**

204 As the primary endpoints, 18 patients in each group obtained effective outcomes from the
205 treatments. Efficacy rates and recurrence rates were not statistically significantly different
206 (Fig. 3). The ESR and CRP levels were statistically similar in the two groups at the time of
207 drug withdrawal (Table 2).

208 **Secondary endpoints**

209 Regarding the secondary endpoints, PTH and SBP were significantly different between the
210 two groups at the end of treatment. The PTH (28.8 vs 38.9 pg/ml, $p=0.011$) and mean SBP
211 (113.9 vs 122.4 mmHg, $p=0.023$) at the time of withdrawal were significantly lower in the
212 experimental group than in the control group.

213 No differences were observed in FT3, FT4, TSH, cortisol (Table 3), fasting plasma
214 glucose (FPG), breakfast postprandial plasma glucose (BPPG), pre-dinner plasma glucose
215 (PDPG), bedtime plasma glucose (BPG), GA, BCTX, OC, CT, 25-OH-VD, PINP, and TG,
216 TC at baseline (Supplementary table). A difference was observed for baseline DBP, which
217 ultimately did not influence baseline blood pressure or any primary and secondary endpoints.

218 The FT3 and FT4 levels in both groups were significantly reduced compared to those at
219 baseline at the 6th, 12th, 24th week, and resumed to normal reference range after 6 weeks. At
220 the 6th week, the median of FT3 (normal range 3.1-6.8 pmol/L) decreased from 7.85 to 4.4
221 pmol/L in the experimental group and from 8.85 to 4.7 pmol/L in the control group. The
222 median of FT4 (normal range 11-22 pmol/L) decreased from 29.2 to 12.4 pmol/L in the
223 experimental group and from 26.65 to 12.3 pmol/L in the control group. The TSH levels of

224 each group were significantly increased compared to baseline at the 6th, 12th, and 24th week
225 ($p < 0.05$ for all). At the 6th week TSH levels (normal range 0.27-4.20 mIU/L) increased from
226 0.01 to 8.61 mIU/L in the experimental group and from 0.02 to 4.68 mIU/L in the control
227 group, both exceeding the upper limit of normal values, and fell to normal levels at the 12th
228 and 24th week (Table 3). The incidences of transient overt and subclinical hyperthyroidism at
229 diagnosis were 86% (43/50) (Fig. 4a), 81% (21/26), and 92% (22/24) in the general group,
230 experimental group, and control group, respectively. The incidences of transient overt and
231 subclinical hypothyroidism during follow-up period were 61% (30/49) (Fig. 4b), 72% (18/25),
232 and 50% (12/24) in the general group, experimental group, and control group, respectively.
233 Cortisol levels in the experimental and control groups were both significantly decreased to
234 similar levels, from 393.1 and 276.2 mmol/L (baseline) to 58.3 and 58.57 mmol/L after 1
235 week of treatment (Table 3), respectively.

236 Compared with baseline levels, the mean FPG, BPPG, and GA levels were significantly
237 decreased at the time of drug withdrawal in both groups. Mean FPG reduced by 0.9 mmol/L
238 in the experimental group and 0.61 mmol/L in the control group. Mean BPPG reduced by
239 1.09 mmol/L in the experimental group and 0.89 mmol/L in the control group. Mean GA
240 levels reduced by 1.81% in the experimental group and 2.06% in the control group.
241 Furthermore, the mean PDPG of the control group was significantly decreased at the time of
242 drug withdrawal compared with baseline (Supplementary table 1).

243 The median PINP in the experimental group (increased to 47.14 ng/mL) and in the
244 control group (increased to 45.46 ng/mL) was significantly elevated at the time of withdrawal
245 compared with baseline. The mean OC level in the control group (increased to 23.1 ng/mL)

246 was significantly increased at the time of drug withdrawal compared to baseline. TG and TC
247 levels of the two treatment groups were significantly increased at the time of drug withdrawal
248 compared to baseline (TG increased by 0.44 mmol/L in the experimental group and 0.52
249 mmol/L in the control group, TC increased by 1.82 mmol/L in the experimental group and 1.42
250 mmol/L in the control group) (Supplementary table 2).

251 A total of 14 patients developed recurrence and received the new treatment method.
252 Withdrawal occurred in 92.9% of all relapsed patients after 4 weeks of therapy, except one
253 patient whose treatment was discontinued at the 7th week.

254 **Discussion**

255 We designed a randomized controlled trial to evaluate feasibility of short-term prednisone as
256 a strategy for treating moderate-to-severe symptoms of SAT. Furthermore, our goal was to
257 minimize the side effects of glucocorticoids while maintaining efficacy. We therefore
258 administered prednisone for 1 week and then switched to NSAIDs for 1 week in patients in
259 the experimental group. During the 24-week follow-up period, the experimental group
260 showed non-inferior efficacy compared with the control group, with fewer side effects.

261 Owing to the wide-range of suppressive effects on chemical mediators [18], patients
262 receiving corticosteroids for SAT had a shorter time period to symptom resolution compared
263 with those treated with NSAIDs [19]. Therefore, the guidelines recommend that patients
264 failing to respond to NSAIDs or those with moderate-to-severe symptoms should be treated
265 with corticosteroids such as prednisone 40 mg daily for 1-2 weeks [1]. Doses should be
266 gradually tapered over 2-4 or 4-6 weeks after relief of symptoms [20]. However, the slow
267 reduction results in a long course of treatment, more than 8 weeks in some cases [3]. One

268 study recommended corticosteroid withdrawal until iodine uptake resumed to normal. The
269 course of treatment was at least 76 days [17]. Even short-term glucocorticoid use for less than
270 30 days increased the incidence of sepsis, venous thromboembolism, and fracture [21]. Thus,
271 managing the side effects of glucocorticoids is challenging. The ideal treatment options
272 include minimized effective doses or keeping the course as short as possible [3]. At present,
273 RCTs examining shorter courses of prednisone are lacking. In general, patients given acute
274 corticosteroid therapy (< 7-14 days) do not develop HPA axis suppression. As a result,
275 treatment can be suspended [22]. Similar to another study [12], the ESR was still elevated
276 after 1 week administration of 30 mg prednisone daily in our preliminary experiment.
277 Additionally, NSAIDs are considered as a first-line therapy to relieve pain in SAT with mild
278 symptoms. Subsequently, we added 1 week of celecoxib in the short-term group, with the aim
279 to eliminate SAT completely. Therefore, the RCT was conducted using 1 week of prednisone,
280 then 1 week of NSAIDs, compared with the 6-week regimen recommended by the Chinese
281 guidelines.

282 Our research demonstrated that the experimental and control groups had similar efficacy
283 and recurrence rates, consistent with previous studies [12,13,16]. Recurrence is frequent and
284 can occur at any time during or after treatment [11]. In the experimental group, 3 patients
285 relapsed during the treatment period, and 5 relapsed after withdrawal. In the control group,
286 recurrence occurred in 2 patients during the treatment period and 4 patients after withdrawal.
287 These recurrence characteristics reminded us that the relapse was possible after withdrawal.
288 As the dosage was decreased, approximately 20% of patients relapsed and required
289 restoration of the higher dose [16]. In our research, treatment using 10 mg prednisone in the

290 morning and 10 mg in the afternoon was used for relapse management.

291 At present, there is no one systematic review to assess mild and overlooked influences of
292 glucocorticoid, such as on blood glucose and blood pressure, during SAT treatment [3]. We
293 first systematically observed these side effects. At the end of treatment, SBP was lower (by
294 approximately 10 mmHg) in the experimental group than in the control group, which
295 indicated that short-term prednisone might have less effect on SBP. Increased plasma
296 volume, elevated peripheral vascular resistance and heightened cardiac output are the
297 possible mechanisms contributing to the development of hypertension with glucocorticoid
298 excess. Increased plasma volume may be related to long-term glucocorticoids acting on
299 mineralocorticoid receptors [23]. We also found elevated PTH levels, even if prednisone was
300 taken only for 1 week. Similarly, PTH was significantly lower (by approximately 10 pg/mL)
301 in the experimental group than in the control group. Glucocorticoid inhibits calcium
302 absorption in the small intestine by affecting vitamin D, thereby reducing serum calcium and
303 slightly elevating PTH, which leads to secondary osteoporosis [24]. Moreover, PINP, the
304 indirect marker of bone formation, was elevated at withdrawal compared with that at
305 baseline in both groups, which indicated that prednisone could affect bone formation even if
306 the course of treatment was only 1 week. Similar to a previous study [25], we observed that
307 prednisone can significantly elevate blood lipids, such as TG and TC, even with short-term
308 use. In addition, FPG, BPPG, and GA were all decreased, suggesting that the
309 glucose-lowering effect of pain relief during stress may be stronger than the
310 hyperglycemic effect that antagonizes insulin after prednisone use. Increased OC and
311 decreased PDPG at withdrawal, compared with that at baseline in the control group, showed

312 only a changing trend with no significant difference in the experimental group. These may
313 reach statistical difference after expanding the sample size. The symptomology of chronic
314 adrenal insufficiency was not observed, and there was no life-threatening acute adrenal
315 crisis in the two groups.

316 Although many researchers deemed transient hyperthyroidism and hypothyroidism are
317 universal after SAT, we determined permanent hypothyroidism may not be so common. In
318 our study, the incidences of temporary hyperthyroidism and hypothyroidism were much
319 higher than enrolled patients in other trials [1]. We speculated that the higher incidence
320 compared to previous studies in our study which may have included more severe patients
321 with thyroid follicle damage. These patients likely experienced transient hyperthyroidism and
322 slow thyroid follicle repair, leading to lower thyroid hormones levels to stimulate pituitary
323 TSH secretion. The incidence of persistent hypothyroidism is 5-15% [1], and patients with
324 permanent hypothyroidism require life-long thyroxine therapy [16]. There were only 2
325 patients with negative thyroid autoantibodies who had “persistent hypothyroidism” during the
326 24-week follow-up period. However, levothyroxine dose gradually reduced until ultimate
327 withdrawal along with the extension of follow-up period to 3 years 8 months and 4 years,
328 respectively. The follow-up time in one study [26] was long enough to be similar to our
329 findings, without occurrences of persistent hypothyroidism.

330 It's our novelty that we introduced the scoring criteria [6] to calculate symptom
331 severity scores of patients in this study (Fig. 4c). Two studies [27, 28] demonstrated fever
332 development in 46.2% of patients ($>38.3^{\circ}\text{C}$) and 28.2% ($>38^{\circ}\text{C}$) of patients. In this study,
333 40% of patients had fever ($>37^{\circ}\text{C}$), suggesting that fever was common in moderate-to-severe

334 SAT (Fig. 4d). Our results also suggest that the 90% of SAT cases occurred in the spring,
335 autumn and winter months in China (Fig. 4e). Different seasonal clusters during summer to
336 early autumn [27] and in the late summer and autumn [29] have been reported in other
337 countries. Consistent with the literature [30], the predilection is 86% in those aged 30-60
338 years and especially 42% in those aged 40-50 years (Fig. 4f). Similar to American
339 communities [4], women were more susceptible to SAT, and the ratio of female to male cases
340 was 4:1 (Fig. 4g). Mild anemia was common, with an incidence rate of 68% (Fig. 4h). Our
341 average time to definite diagnosis was 4.46 weeks (Fig. 4i), suggesting that the disease was
342 easily missed initially. When thyroid enlargement was assessed by palpation, the rate of
343 normalization after 7 days of prednisone treatment was 100%. After 24 and 48 hours
344 treatment, the pain relief rates were 90% and 98%, suggesting that prednisone is a
345 particularly effective drug for moderate-to-severe SAT. Similar to several other reports [6, 11,
346 28], our positive rates of TPOAb and TGAb were 20.41% and 37.5%. TRAb is often
347 significantly elevated in patients with Graves' disease. In this research, the rate of TRAb
348 exceeding the upper limit of normal was 2.33%, suggesting that TRAb is a valuable indicator
349 for differentiating Graves' disease from hyperthyroidism caused by SAT. TBG levels have
350 been used as a marker for monitoring early-phase SAT [12]. The rate of TBG exceeding the
351 normal value in our study was 72.73%, suggesting that thyroid follicular destruction and
352 TBG release are common phenomena in SAT. Similar to other reports [29], there was a low
353 RAIU, which could be used to distinguish this condition from Graves' disease during the
354 toxic phase of SAT.

355 The present study had several limitations. First, we did not analyze that the side effects

356 of celecoxib, which may have affected the experimental results. Second, our study included a
357 small sample size; thus, the results should be verified in a larger sample size. Third, this was
358 a single-center and single-blinded study, which limits the strength of our findings. A
359 double-blinded, multicenter study would be the next step.

360 **Conclusions**

361 Overall, current treatment recommendations are based on observational data and expert
362 opinion. This is the first randomized controlled trial to evaluate the efficacy and safety of
363 1-week vs 6-week treatment for moderate-to-severe SAT. Our study demonstrated that the
364 two groups had similar rates of effectiveness and recurrence. Furthermore, the short-term
365 treatment had fewer side effects with respect to bone metabolism and blood pressure.
366 Short-term glucocorticoid with a better safety profile may be likely an optional strategy for
367 moderate-to-severe SAT.

368

369 **Abbreviations**

370 SAT: Subacute thyroiditis; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein;
371 NSAIDs: Nonsteroidal anti-inflammatory drugs; RCTs: Randomized controlled trials; Hb:
372 Hemoglobin; TSH: Thyroid-stimulating hormone; FT3: Free triiodothyronine; FT4: Free
373 thyroxine; GA: Glycated albumin; TC: Total cholesterol; TG: Triglyceride; SBP: Systolic
374 blood pressure; DBP: Diastolic blood pressure; BCTX: β cross-linked C-telopeptide of type
375 I collagen; OC: osteocalcin; PINP: Type I procollagen amino terminal peptide; PTH:
376 Parathyroid hormone; 25-OH-VD: 25-hydroxy vitamin D; CT: Calcitonin; TGAb:
377 Anti-thyroglobulin antibody; TPOAb: Anti-thyroid peroxidase antibody; TBG:

378 Thyroid-binding globulin; TRAb: Anti-TSH receptor antibody; RAIU: Radioiodine uptake;

379 FPG: Fasting plasma glucose; BPPG: Breakfast postprandial plasma glucose; PDPG:

380 Pre-dinner plasma glucose; BPG: Bedtime plasma glucose

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400 **Declarations**

401 **Ethics approval and consent to participate**

402 This study was approved by the Ethics Committee of Xinqiao Hospital, Third Military
403 Medical University, China (reference number 2018012-01).

404 **Consent for publication**

405 Participants provided written informed consent for publication of research results.

406 **Availability of data and materials**

407 The datasets generated and/or analysed during the current study are not publicly available due
408 to individual privacy but are available from the corresponding author on reasonable request.

409 **Competing interests**

410 The authors declare that they have no competing interests.

411 **Funding**

412 This work was supported by the grant from Clinical Research Project of Xinqiao Hospital of
413 Third Military Medical University (grant numbers Yclkt-201421), Key Laboratory Incubation
414 Project of the Third Affiliated Hospital of Chongqing Medical University (Jie er Hospital)
415 (grant numbers KY19025) and High-level Medical Reserved Personnel Training Project of
416 Chongqing (grant numbers RC18004). The funding source had no influence on the design and
417 conduct of the study; collection, management, analysis and interpretation of the data;
418 preparation, review or approval of the manuscript; or the decision to submit the manuscript
419 for publication.

420 **Authors' contributions**

421 LD was involved with the literature search, study design, clinical diagnosis, patient
422 follow-up, data collection and writing of the first and revised draft of the manuscript. XF, RZ,
423 XT, XX, SF and HZ were chief investigator. SF was involved with revision of the
424 manuscript. All other authors critically reviewed and approved the final version.

425 **Acknowledgments**

426 The authors would like to thank Yetao Luo and Yuan Liu for statistical analysis.

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443 **References**

- 444 1. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA,
445 Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines
446 for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.
447 *Thyroid*. 2016;26(10):1343-1421.
- 448 2. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P,
449 McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN. Hyperthyroidism and
450 Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid
451 Association and American Association of Clinical Endocrinologists. *Thyroid*.
452 2011;21(6):593-646.
- 453 3. Kubota S, Nishihara E, Kudo T, Ito M, Amino N, Miyauchi A. Initial Treatment with
454 15 mg of Prednisolone Daily Is Sufficient for Most Patients with Subacute Thyroiditis in
455 Japan. *Thyroid*. 2013;23(3):269-272.
- 456 4. Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of
457 glucocorticoids. *Expert Opin Drug Saf*. 2016;15(4):457-465.
- 458 5. Broersen LHA, Pereira AM, Jørgensen JOL, Dekkers OM. Adrenal Insufficiency in
459 Corticosteroids Use: Systematic Review and Meta-Analysis. *J Clin Endocrinol Metab*.
460 2015;100(6):2171-2180.
- 461 6. Benbassat CA, Olchovsky D, Tsvetov G, Shimon I. Subacute thyroiditis: Clinical
462 characteristics and treatment outcome in fifty-six consecutive patients diagnosed between
463 1999 and 2005. *J Endocrinol Invest*. 2007;30(8):631-635.
- 464 7. Koirala KP, Sharma V. Treatment of Acute Painful Thyroiditis with Low Dose

-
- 465 Prednisolone: A Study on Patients from Western Nepal. *J Clin Diagn Res.* 2015;9(9):
466 MC01-03
- 467 8. Arao T, Okada Y, Torimoto K, Kurozumi A, Narisawa M, Yamamoto S, Tanaka Y.
468 Prednisolone Dosing Regimen for Treatment of Subacute Thyroiditis. *J UOEH.*
469 2015;37(2):103-10.
- 470 9. Floriani C, Feller M, Aubert CE, M'Rabet-Bensalah K, Collet TH, den Elzen WPJ, Bauer
471 DC, Angelillo-Scherrer A, Aujesky D, Rodondi N. Thyroid Dysfunction and Anemia: A
472 Prospective Cohort Study and a Systematic Review. *Thyroid.* 2018;28(5):575-582.
- 473 10. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R,
474 Singer PA, Woeber KA. Clinical practice guidelines for hypothyroidism in adults:
475 cosponsored by the American Association of Clinical Endocrinologists and the American
476 Thyroid Association. *Thyroid.* 2012;22(12):1200-1235.
- 477 11. Fatourechhi V, Aniszewski JP, Fatourechhi GZE, Atkinson EJ, Jacobsen SJ. Clinical
478 Features and Outcome of Subacute Thyroiditis in an Incidence Cohort: Olmsted County,
479 Minnesota, Study. *J Clin Endocrinol Metab.* 2003;88(5):2100-2105.
- 480 12. Mizukoshi T, Noguchi S, Murakami T, Futata T, Yamashita H. Evaluation of recurrence
481 in 36 subacute thyroiditis patients managed with prednisolone. *Intern Med.*
482 2001;40(4):292-295.
- 483 13. Bennedbaek FN, Hegedus L. The value of ultrasonography in the diagnosis and follow-up
484 of subacute thyroiditis. *Thyroid.* 1997;7(1):45-50.
- 485 14. Topuzovic N, Smoje J, Karner I. The therapeutic approach in subacute (de Quervain's)
486 thyroiditis. *J Nucl Med.* 1997;38(10):1665.

-
- 487 15. Yamada T, Sato A, Aizawa T. Dissociation between serum interleukin-6 rise and other
488 parameters of disease activity in subacute thyroiditis during treatment with corticosteroid. *J*
489 *Clin Endocrinol Metab.* 1996;81(2):577-579.
- 490 16. Volpe R. The management of subacute (DeQuervain's) thyroiditis. *Thyroid.*
491 1993;3(3):253-255.
- 492 17. Vagenakis AG, Abreau CM, Braverman LE. Prevention of recurrence in acute thyroiditis
493 following corticosteroid withdrawal. *J Clin Endocrinol Metab.* 1970;31(6):705-708.
- 494 18. Cunningham FM, Lees P. Advances in anti-inflammatory therapy. *Br Vet J.*
495 1994;150(2):115-134.
- 496 19. Sato J, Uchida T, Komiya K, Goto H, Takeno K, Suzuki R, Honda A, Himuro
497 M, Watada H. Comparison of the therapeutic effects of prednisolone and nonsteroidal
498 anti-inflammatory drugs in patients with subacute thyroiditis. *Endocrine.*
499 2017;55(1):209-214.
- 500 20. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. *N Engl J Med.*
501 2003;348(26):2646-2655.
- 502 21. Waljee AK, Rogers MAM, Lin P, Singal AG, Stein JD, Marks RM, Ayanian
503 JZ, Nallamotheu BK. Short term use of oral corticosteroids and related harms among adults in
504 the United States: population based cohort study. *BMJ.* 2017;357:j1415.
- 505 22. Alves CE, Sio, Robazzi TCV, Ccedil M, A M. Withdrawal from glucocorticosteroid
506 therapy: clinical practice recommendations. *J Pediatr (Rio J).* 2008;84(3):192-202.
- 507 23. Pimenta E, Wolley M, Stowasser M. Adverse Cardiovascular Outcomes of Corticosteroid
508 Excess. *Endocrinology.* 2012;153(11):5137-5142.

-
- 509 24. Mirza F, Canalis E. Management of endocrine disease: Secondary osteoporosis:
510 pathophysiology and management. *Eur J Endocrinol.* 2015;173(3):R131-R151.
- 511 25. Taskinen MR, Kuusi T, Yki-Jarvinen H, Nikkila EA. Short-term effects of prednisone on
512 serum lipids and high density lipoprotein subfractions in normolipidemic healthy men. *J Clin*
513 *Endocrinol Metab.* 1988;67(2):291-299.
- 514 26. Alfadda AA, Sallam RM, Elawad GE, AlDhukair H, Alyahya MM. Subacute Thyroiditis:
515 Clinical Presentation and Long Term Outcome. *Int J Endocrinol.* 2014;2014:794943.
- 516 27. Nishihara E, Ohye H, Amino N, Takata K, Arishima T, Kudo T, Ito M, Kubota S, Fukata
517 S, Miyauchi A. Clinical characteristics of 852 patients with subacute thyroiditis before
518 treatment. *Intern Med.* 2008;47(8):725-729.
- 519 28. Erdem N, Erdogan M, Ozbek M, Karadeniz M, Cetinkalp S, Ozgen AG, Saygili F, Yilmaz
520 C, Tuzun M, Kabalak T. Demographic and clinical features of patients with subacute
521 thyroiditis: results of 169 patients from a single university center in Turkey. *J Endocrinol*
522 *Invest.* 2007;30(7):546-550.
- 523 29. Sweeney LBM, Stewart CM, Gaitonde DYM. Thyroiditis: An Integrated Approach. *Am*
524 *Fam Physician.* 2014;90(6):389-396.
- 525 30. Singer PA. Thyroiditis. Acute, subacute, and chronic. *Med Clin North Am.*
526 1991;75(1):61-77.
- 527
- 528
- 529
- 530

531 Table 1 Baseline characteristics

| Characteristic | Short-term treatment (n=26) | 6-weeks treatment (n=24) | Statistical magnitude | P-value |
|----------------|-----------------------------|--------------------------|-----------------------|--------------------|
| Age (year) | 45.54±8.87 | 44.08±9.51 | 0.56 ^T | 0.578 |
| Gender | 20(76.92%) | 20(83.33%) | / | 0.728 ^F |
| Severity score | 4(3-6) | 4(3-4.5) | -1.191 ^Z | 0.233 |
| 3h RAIU (%) | 1.45(1.2-1.7) | 1.45(1.15-1.7) | -0.029 ^Z | 0.977 |
| 24h RAIU (%) | 1.15(0.3-1.8) | 1.6(1.05-1.95) | 0.065 ^Z | 0.129 |
| Hb (g/L) | 115.5(111.0-124.0) | 114.5(110-126.5) | 0.204 ^Z | 0.838 |
| TPOAb | 10(5-24) | 17(6-40) | 0.969 ^Z | 0.322 |
| TGAb (iu/mL) | 47.5(32.5-121.8) | 50.6(35.75-507.9) | 0.740 ^Z | 0.459 |
| TBG (ug/L) | 199.05(42-372.6) | 182.5(90.6-347.7) | 0.248 ^Z | 0.805 |
| TRAb (iu/L) | 0.4(0.3-0.6) | 0.3(0.3-0.7) | -0.787 ^Z | 0.431 |

532 h=hour, RAIU=radioiodine uptake, Hb=hemoglobin, TPOAb=anti-thyroid peroxidase

533 antibody, TGAb=anti-thyroglobulin antibody, TBG=thyroid binding globulin, TRAb=

534 anti-TSH receptor antibody.

535 ^ZZ-value of Wilcoxon rank test for two independent samples, ^TT-value of two independent

536 samples t-test, ^FP-value of the fisher's exact test.

537

538

539 Table 2 Comparisons for ESR and CRP between the two groups

| Characteristic | Time frame | Short-term treatment (n=26) | 6-weeks treatment (n=24) | Statistical magnitude | P-value |
|----------------|------------|-----------------------------|--------------------------|-----------------------|---------|
| ESR (mm/H) | Baseline | 65.5 (44-81) | 66 (41.5-73.5) | 0.29 ^{F1} | 0.596 |
| | 1 week | 15.5 (11-34) | 17.5 (10-42) | 122.47 ^{F2} | <0.001 |
| | Withdrawal | 15 (10-24) | 9 (6-17) | 1.59 ^{F3} | 0.215 |
| CRP (mg/L) | Baseline | 27 (15-65) | 26 (15.5-42.5) | 0.01 ^{F1} | 0.984 |
| | 1 week | 5 (5-5) | 5 (5-5) | 18.68 ^{F2} | <0.001 |
| | Withdrawal | 5 (5-6.5) | 5 (5-10.2) | 0.29 ^{F3} | 0.748 |

540 ESR=erythrocyte sedimentation rate, CRP=c-reactive protein.

541 ^{F1}F-value group effects of generalized linear mixed model (GLMM), ^{F2}F-value time effects of

542 GLMM, ^{F3}F-value group * time effects of GLMM.

543

544

545

546

547

548

549

550

551

552

553 Table 3 Comparisons for thyroid function and cortisol between the two groups

| Characteristic | Time frame | Short-term treatment (n=26) | 6-weeks treatment (n=24) | Statistical magnitude | P-value |
|----------------------|------------|--|---------------------------------------|--------------------------|---------|
| FT3 (pmol/L) | Baseline | 7.85 (7.4-11.1) ^{6,12,24} | 8.85 (7.55-12.65) ^{6,12,24} | 0.03 ^{F1} | 0.856 |
| | 6 weeks | 4.4 (4.1-5) ^{B,12,24} | 4.7 (4.1-5.08) ^{B,24} | 21.49 ^{F2} | <0.001 |
| | 12 weeks | 4.8 (4.3-5.2) ^{B,6} | 4.5 (4.1-4.86) ^B | 5.06 ^{F3} | 0.0042 |
| | 24 weeks | 4.7 (4.4-5.2) ^{B,6,A} | 4.41 (4.1-4.9) ^{B,6,A} | | |
| FT4 (pmol/L) | Baseline | 29.2 (23-41.9) ^{6,12,24} | 26.65 (21.75-35.5) ^{6,12,24} | 0.27 ^{F1} | 0.605 |
| | 6 weeks | 12.4 (10-13.9) ^{B,12,24} | 12.3 (11.1-14.0) ^B | 40.96 ^{F2} | <0.001 |
| | 12 weeks | 13.1 (12.1-14.2) ^{B,6,24} | 12.8 (12.2-13.7) ^B | 3.08 ^{F3} | 0.037 |
| | 24 weeks | 15.3 (12.7-16.5) ^{B,6,12,A} | 13.5 (11.8-14.6) ^{B,A} | | |
| TSH (mIU/L) | Baseline | 0.01 (0.01-0.05) ^{6,12,24} | 0.02 (0.01-0.98) ^{6,12,24} | 0.46 ^{F1} | 0.502 |
| | 6 weeks | 8.61 (4.17-12.71) ^{B,12,24,A} | 4.68 (2.59-6.07) ^{B,A} | 33.10 ^{F2} | <0.001 |
| | 12 weeks | 4.2 (2.86-6.17) ^{B,6} | 3.75 (2.71-7.24) ^B | 2.94 ^{F3} | 0.043 |
| | 24 weeks | 3.47 (2.62-4.39) ^{B,6} | 2.97 (2.17-4.96) ^B | | |
| Cortisol (nmol/L) | Baseline | 393.1±273.1 | 276.2±249.7 | 4.35 ^{F1} | 0.042 |
| | 1 week | 58.3±40 | 58.57±57.85 | 93.66 ^{F2} | <0.001 |
| | Withdrawal | 325.9±160.6 | 250.1±102.4 | 2.93 ^{F3} | 0.063 |

554 FT3=Free triiodothyronine, FT4=Free thyroxine, TSH=Thyrotropin.

555 ^{F1}F-value group effects of GLMM, ^{F2}F-value time effects of GLMM, ^{F3}F-value group * time

556 effects of GLMM. In the GLMM, A representative significant difference in the experimental

557 group and the control group at each time point, P<0.05. B, 6, 12, 24 representative significant

558 difference in the experimental group or the control group in the baseline, 6 weeks, 12 weeks,
559 24 weeks, respectively, $P < 0.05$.

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580 **Figure Legends**

581 **Figure 1** Trial profile

582 PDN=Prednisone.

583 **Figure 2** Study protocol

584 PDN=Prednisone.bid=twice daily. W=week.

585 **Figure 3** The effective and recurrent rates between experimental and control groups

586 **Figure 4** Other epidemiological data

587 a The incidence of subclinical hyperthyroidism, overt hyperthyroidism, and euthyroidism in
588 the general group at diagnosis

589 b The incidences of subclinical hypothyroidism, overt hypothyroidism, and euthyroidism in
590 the general group during the 24-weeks follow-up period

591 c The severity score distribution was based on the symptoms of SAT

592 d The fever condition in the general group at diagnosis

593 e The seasonal distribution in the general group at diagnosis


594 f The age distribution in the general group at diagnosis


595 g The gender proportion in the general group at diagnosis


596 h The proportion of anemia in the general group at diagnosis









597 i The diagnostic time after onset of this research

598







a Thyroid function at diagnosis**b** Thyroid function during follow-up period**c** Severity score distribution**d** Fever at diagnosis**e** Seasonal distribution**f** Age distribution**g** Gender proportion**h** Proportion of anemia**i** Diagnostic time after onset